ERBB2 and breast carcinoma: Trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival (PFS) in HER2-low breast cancer in the DESTINY-Breast04 trial (10.1 vs. 5.4 months; HR = 0.51), although men made up less than 1% of the trial cohort [4–6].